Evidence map›Paper›PMID 34769456›Full record

ArticleInternational journal of molecular sciences2021

GPI-80 Augments NF-κB Activation in Tumor Cells.

Yuji Takeda, Yuta Kurota, Tomoyuki Kato, Hiromi Ito, Akemi Araki, Hidetoshi Nara, Shinichi Saitoh, Nobuyuki Tanaka, Norihiko Tsuchiya, Hironobu Asao

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Yuji TakedaDepartment of Immunology, Faculty of Medicine, Yamagata University, Yamagata 990-9585, Japan.ORCID 0000-0002-0823-1802
Yuta KurotaDepartment of Urology, Faculty of Medicine, Yamagata University, Yamagata 990-9585, Japan.
Tomoyuki KatoDepartment of Urology, Faculty of Medicine, Yamagata University, Yamagata 990-9585, Japan.
Hiromi ItoDepartment of Urology, Faculty of Medicine, Yamagata University, Yamagata 990-9585, Japan.
Akemi ArakiDepartment of Immunology, Faculty of Medicine, Yamagata University, Yamagata 990-9585, Japan.
Hidetoshi NaraDepartment of Immunology, Faculty of Medicine, Yamagata University, Yamagata 990-9585, Japan.
Shinichi SaitohDepartment of Immunology, Faculty of Medicine, Yamagata University, Yamagata 990-9585, Japan.ORCID 0000-0001-7523-8177
Nobuyuki TanakaDivision of Cancer Biology and Therapeutics, Miyagi Cancer Center Research Institute, Natori 981-1293, Japan.
Norihiko TsuchiyaDepartment of Urology, Faculty of Medicine, Yamagata University, Yamagata 990-9585, Japan.
Hironobu AsaoDepartment of Immunology, Faculty of Medicine, Yamagata University, Yamagata 990-9585, Japan.ORCID 0000-0002-1051-4799
Yamagata University · JPMiyagi Prefectural Hospital Organization · JP

Funding

Grant-in-Aid for Scientific Research No. 17K11122
6 · The paper itself

Abstract

Recent studies have discovered a relationship between glycosylphosphatidylinositol (GPI)-anchored protein 80 (GPI-80)/VNN2 (80 kDa GPI-anchored protein) and malignant tumors. GPI-80 is known to regulate neutrophil adhesion; however, the action of GPI-80 on tumors is still obscure. In this study, although the expression of GPI-80 mRNA was detectable in several tumor cell lines, the levels of GPI-80 protein were significantly lower than that in neutrophils. To clarify the function of GPI-80 in tumor cells, GPI-80-expressing cells and GPI-80/VNN2 gene-deleted cells were established using PC3 prostate cancer cells. In GPI-80-expressing cells, GPI-80 was mainly detected in vesicles. Furthermore, soluble GPI-80 in the conditioned medium was associated with the exosome marker CD63 and was also detected in the plasma obtained from prostate cancer patients. Unexpectedly, cell adhesion and migration of GPI-80-expressing PC3 cells were not modulated by anti-GPI-80 antibody treatment. However, similar to the GPI-80 family molecule, VNN1, the pantetheinase activity and oxidative state were augmented in GPI-80-expressing cells. GPI-80-expressing cells facilitated non-adhesive proliferation, slow cell proliferation, NF-κB activation and IL-1β production. These phenomena are known to be induced by physiological elevation of the oxidative state. Thus, these observations indicated that GPI-80 affects various tumor responses related to oxidation.

Indexed as

AgedAmidohydrolasesCase-Control StudiesCell Adhesion MoleculesCell Line, TumorCell MovementCell ProliferationGPI-Linked ProteinsHumansMaleMiddle AgedNeutrophilsNF-kappa BProstatic NeoplasmsSignal TransductionAmidohydrolasesCell Adhesion MoleculesGPI-Linked ProteinsNF-kappa BVNN2 protein, humanIL-1βNF-κBoxidative stresspantetheinaseprostate cancer cells

Identifiers

PMID34769456
PMCPMC8584666
OpenAlexW3213087108

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.